[68Ga]Pentixafor |
|
Phase 3 Clinical |
The University Of Iowa |
Lymphoma, B-Cell, Marginal Zone; Cushing Syndrome; Sarcoidosis; Rejection of organ transplantation; Neuroendocrine Tumors; Myocarditis; Central Nervous System Lymphoma; Hyperaldosteronism |
Details
|
90Y-Pentixather |
|
Phase 2 Clinical |
University Of Wurzburg, Technical University Of Munich |
Multiple Myeloma; Central Nervous System Lymphoma |
Details
|
177Lu-Pentixather |
|
Phase 2 Clinical |
Technical University Of Munich, Nantes University Hospital, University Of Wurzburg |
Leukemia; Multiple Myeloma |
Details
|
Ulocuplumab |
MDX-1338; BMS-936564 |
Phase 2 Clinical |
Bristol-Myers Squibb Company |
Leukemia; Solid tumours; Multiple Myeloma; Lymphoma, Follicular; Leukemia, B-Cell; Waldenstrom Macroglobulinemia; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
MSX-122 |
Q-122; WZ-40; MSX-122 |
Phase 2 Clinical |
Altiris Therapeutics |
Solid tumours; Hot Flashes |
Details
|
PTX-9908 |
PTX-9908 |
Phase 2 Clinical |
Pertinax Therapeutics |
Carcinoma, Hepatocellular |
Details
|
Plerixafor/Tacrolimus Hydrate |
MRG-001(MedRegen); AMD3100+FK506 |
Phase 2 Clinical |
MedRegen LLC |
Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Abdominal Injuries; Wounds and Injuries |
Details
|
NRP-2945 |
NNZ-4945; NRP-2945 |
Phase 2 Clinical |
Neuren Pharmaceuticals Ltd |
Epilepsy |
Details
|
GPC-100 |
GPC-100 |
Phase 2 Clinical |
GPCR Therapeutics USA Inc |
Multiple Myeloma |
Details
|
4-P-021 |
4P021; 4-P-021 |
Phase 2 Clinical |
4P-Pharma Ltd, University of Bordeaux, Institut Pasteur De Lille |
Coronavirus Disease 2019 (COVID-19) |
Details
|
CGT-1881 |
CGT1881; CGT-1881 |
Phase 2 Clinical |
Cgenetech(Suzhou China) Co Ltd |
Hematologic Neoplasms; Hematopoietic stem cell transplantation (HSCT); Multiple Myeloma; Lymphoma, Non-Hodgkin |
Details
|
LY-2510924 |
T-134; LY-2510924 |
Phase 1 Clinical |
Eli Lilly And Company |
Leukemia; Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma |
Details
|
AGT 103-T |
AGT 103-T |
Phase 1 Clinical |
American Gene Technologies International Inc |
HIV Infections |
Details
|
Balixafortide |
POL-6326 |
Phase 1 Clinical |
Polyphor Ltd |
Leukemia, Myelogenous, Chronic; Myelodysplastic Syndromes; Myeloproliferative Disorders; Multiple Myeloma; Breast Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
JVS-100 |
JVS-100; SRX-100; ACRX-100; GP-51801; GP51801 |
Phase 1 Clinical |
Cleveland Clinic |
Heart Failure; Ischemia; Surgical Wound; Peripheral Arterial Disease |
Details
|
Dociparstat sodium |
ODSH; CX-01; PGX-100; PGX-ODSH-2013-AML-1 |
Phase 1 Clinical |
Paringenix |
Coronavirus Disease 2019 (COVID-19); Pancreatic Neoplasms; Myelodysplastic Syndromes; Protein-Losing Enteropathies; Pulmonary Disease, Chronic Obstructive; Leukemia, Myeloid, Acute; Acute Lung Injury |
Details
|
203-Lead Pentixather |
|
Phase 1 Clinical |
National Institutes Of Health, National Cancer Institute, Holden Comprehensive Cancer Center |
Small Cell Lung Carcinoma; Lung Neoplasms |
Details
|
212-Lead Pentixather |
|
Phase 1 Clinical |
National Institutes Of Health, National Cancer Institute, Holden Comprehensive Cancer Center |
Small Cell Lung Carcinoma; Lung Neoplasms |
Details
|
68Ga-Pentixather |
68Ga-Pentixather |
Phase 1 Clinical |
Peking Union Medical College Hospital |
Multiple Myeloma |
Details
|
CXCR4 modified anti-BCMA CAR T cell therapy (Sichuan University) |
|
Phase 1 Clinical |
Sichuan University |
Multiple Myeloma |
Details
|
AD-214 |
AD-214 |
Phase 1 Clinical |
Addpharma Inc, Adalta Ltd |
Lung Diseases, Interstitial; Gastroesophageal Reflux |
Details
|
X-4136 |
X-4136 |
Clinical |
X4 Pharmaceuticals Inc |
Lymphoma, B-Cell; Uterine Cervical Neoplasms; Melanoma |
Details
|
[18F]AlF-NOTA-pentixather |
|
|
Sichuan Provincial People'S Hospital |
|
Details
|
[68Ga]Pentixafor |
|
Phase 3 Clinical |
The University Of Iowa |
Lymphoma, B-Cell, Marginal Zone; Cushing Syndrome; Sarcoidosis; Rejection of organ transplantation; Neuroendocrine Tumors; Myocarditis; Central Nervous System Lymphoma; Hyperaldosteronism |
Details
|
90Y-Pentixather |
|
Phase 2 Clinical |
University Of Wurzburg, Technical University Of Munich |
Multiple Myeloma; Central Nervous System Lymphoma |
Details
|
177Lu-Pentixather |
|
Phase 2 Clinical |
Technical University Of Munich, Nantes University Hospital, University Of Wurzburg |
Leukemia; Multiple Myeloma |
Details
|
Ulocuplumab |
MDX-1338; BMS-936564 |
Phase 2 Clinical |
Bristol-Myers Squibb Company |
Leukemia; Solid tumours; Multiple Myeloma; Lymphoma, Follicular; Leukemia, B-Cell; Waldenstrom Macroglobulinemia; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
MSX-122 |
Q-122; WZ-40; MSX-122 |
Phase 2 Clinical |
Altiris Therapeutics |
Solid tumours; Hot Flashes |
Details
|
PTX-9908 |
PTX-9908 |
Phase 2 Clinical |
Pertinax Therapeutics |
Carcinoma, Hepatocellular |
Details
|
Plerixafor/Tacrolimus Hydrate |
MRG-001(MedRegen); AMD3100+FK506 |
Phase 2 Clinical |
MedRegen LLC |
Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Abdominal Injuries; Wounds and Injuries |
Details
|
NRP-2945 |
NNZ-4945; NRP-2945 |
Phase 2 Clinical |
Neuren Pharmaceuticals Ltd |
Epilepsy |
Details
|
GPC-100 |
GPC-100 |
Phase 2 Clinical |
GPCR Therapeutics USA Inc |
Multiple Myeloma |
Details
|
4-P-021 |
4P021; 4-P-021 |
Phase 2 Clinical |
4P-Pharma Ltd, University of Bordeaux, Institut Pasteur De Lille |
Coronavirus Disease 2019 (COVID-19) |
Details
|
CGT-1881 |
CGT1881; CGT-1881 |
Phase 2 Clinical |
Cgenetech(Suzhou China) Co Ltd |
Hematologic Neoplasms; Hematopoietic stem cell transplantation (HSCT); Multiple Myeloma; Lymphoma, Non-Hodgkin |
Details
|
LY-2510924 |
T-134; LY-2510924 |
Phase 1 Clinical |
Eli Lilly And Company |
Leukemia; Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma |
Details
|
AGT 103-T |
AGT 103-T |
Phase 1 Clinical |
American Gene Technologies International Inc |
HIV Infections |
Details
|
Balixafortide |
POL-6326 |
Phase 1 Clinical |
Polyphor Ltd |
Leukemia, Myelogenous, Chronic; Myelodysplastic Syndromes; Myeloproliferative Disorders; Multiple Myeloma; Breast Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
JVS-100 |
JVS-100; SRX-100; ACRX-100; GP-51801; GP51801 |
Phase 1 Clinical |
Cleveland Clinic |
Heart Failure; Ischemia; Surgical Wound; Peripheral Arterial Disease |
Details
|
Dociparstat sodium |
ODSH; CX-01; PGX-100; PGX-ODSH-2013-AML-1 |
Phase 1 Clinical |
Paringenix |
Coronavirus Disease 2019 (COVID-19); Pancreatic Neoplasms; Myelodysplastic Syndromes; Protein-Losing Enteropathies; Pulmonary Disease, Chronic Obstructive; Leukemia, Myeloid, Acute; Acute Lung Injury |
Details
|
203-Lead Pentixather |
|
Phase 1 Clinical |
National Institutes Of Health, National Cancer Institute, Holden Comprehensive Cancer Center |
Small Cell Lung Carcinoma; Lung Neoplasms |
Details
|
212-Lead Pentixather |
|
Phase 1 Clinical |
National Institutes Of Health, National Cancer Institute, Holden Comprehensive Cancer Center |
Small Cell Lung Carcinoma; Lung Neoplasms |
Details
|
68Ga-Pentixather |
68Ga-Pentixather |
Phase 1 Clinical |
Peking Union Medical College Hospital |
Multiple Myeloma |
Details
|
CXCR4 modified anti-BCMA CAR T cell therapy (Sichuan University) |
|
Phase 1 Clinical |
Sichuan University |
Multiple Myeloma |
Details
|
AD-214 |
AD-214 |
Phase 1 Clinical |
Addpharma Inc, Adalta Ltd |
Lung Diseases, Interstitial; Gastroesophageal Reflux |
Details
|
X-4136 |
X-4136 |
Clinical |
X4 Pharmaceuticals Inc |
Lymphoma, B-Cell; Uterine Cervical Neoplasms; Melanoma |
Details
|
[18F]AlF-NOTA-pentixather |
|
|
Sichuan Provincial People'S Hospital |
|
Details
|